Oppenheimer reissued their buy rating on shares of Integra Lifesciences (NASDAQ:IART) in a report issued on Friday morning.

A number of other analysts have also recently weighed in on IART. Citigroup raised their price target on shares of Integra Lifesciences from $60.00 to $70.00 and gave the company an outperform rating in a report on Thursday, April 26th. JPMorgan Chase & Co. raised their price target on shares of Integra Lifesciences from $55.00 to $57.00 and gave the company a neutral rating in a report on Thursday, April 26th. Morgan Stanley raised their price target on shares of Integra Lifesciences from $53.00 to $58.00 and gave the company an equal weight rating in a report on Thursday, April 26th. ValuEngine upgraded shares of Integra Lifesciences from a sell rating to a hold rating in a report on Friday, April 27th. Finally, Zacks Investment Research upgraded shares of Integra Lifesciences from a hold rating to a buy rating and set a $69.00 price target on the stock in a report on Tuesday, May 1st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $61.38.

NASDAQ:IART opened at $58.97 on Friday. Integra Lifesciences has a fifty-two week low of $41.51 and a fifty-two week high of $67.50. The stock has a market capitalization of $5.35 billion, a PE ratio of 30.40, a PEG ratio of 1.94 and a beta of 0.57. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.60. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The business had revenue of $366.20 million for the quarter, compared to analysts’ expectations of $368.08 million. During the same period last year, the business earned $0.45 EPS. The company’s revenue was up 29.8% compared to the same quarter last year. equities research analysts forecast that Integra Lifesciences will post 2.4 EPS for the current year.

In related news, VP Glenn Coleman sold 8,916 shares of Integra Lifesciences stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total value of $561,708.00. Following the completion of the sale, the vice president now directly owns 16,795 shares in the company, valued at approximately $1,058,085. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel L. Reuvers sold 1,000 shares of Integra Lifesciences stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $66.97, for a total transaction of $66,970.00. Following the completion of the sale, the vice president now owns 25,009 shares of the company’s stock, valued at $1,674,852.73. The disclosure for this sale can be found here. Insiders sold a total of 271,892 shares of company stock valued at $17,347,342 over the last quarter. 5.10% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in IART. FMR LLC boosted its stake in Integra Lifesciences by 11.8% in the 2nd quarter. FMR LLC now owns 11,078,120 shares of the life sciences company’s stock worth $713,542,000 after purchasing an additional 1,166,483 shares in the last quarter. Millennium Management LLC acquired a new stake in Integra Lifesciences in the 2nd quarter worth approximately $46,263,000. Westwood Holdings Group Inc. acquired a new stake in Integra Lifesciences in the 1st quarter worth approximately $32,180,000. Janus Henderson Group PLC boosted its stake in Integra Lifesciences by 22.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,966,341 shares of the life sciences company’s stock worth $126,652,000 after purchasing an additional 365,254 shares in the last quarter. Finally, Champlain Investment Partners LLC boosted its stake in Integra Lifesciences by 7.6% in the 1st quarter. Champlain Investment Partners LLC now owns 4,997,595 shares of the life sciences company’s stock worth $276,567,000 after purchasing an additional 351,520 shares in the last quarter. Institutional investors own 81.99% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: Average Daily Trade Volume – ADTV

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.